Sign in

    Peter Enderlin

    Portfolio Manager at MAZ Partners

    Peter Enderlin is a Portfolio Manager at MAZ Partners, where he specializes in equity research and portfolio management within the healthcare and biotechnology sectors. He has provided research coverage and investment insight on companies such as Lisata Therapeutics, actively participating in earnings calls and applying a data-driven approach to investment decisions. With experience spanning several years at MAZ Partners, Enderlin is recognized for his analytical rigor and portfolio leadership, though public rankings and detailed investment performance metrics are not widely reported. His professional background also reflects a role at MAZ Capital Advisors and he holds the relevant credentials for portfolio management, with regulatory compliance and securities licensing consistent with industry standards.

    Peter Enderlin's questions to LISATA THERAPEUTICS (LSTA) leadership

    Peter Enderlin's questions to LISATA THERAPEUTICS (LSTA) leadership • Q2 2025

    Question

    Peter Enderlin of MAZ Partners asked a series of questions regarding the extended cash runway, the significance of the new patent extending to 2040, and for a comparison of the regulatory environments in the U.S. versus China.

    Answer

    President, CEO & Director David Mazzo addressed all points. He clarified the cash runway projection only includes a small contribution from the New Jersey NOL program and no other capital infusions. He described the new patent as a fundamental composition of matter patent, the most difficult type to challenge, which significantly secures the company's IP. Lastly, he explained that comparing the U.S. and Chinese regulatory bodies is difficult for a non-Chinese company due to unique relationships and politics in China.

    Ask Fintool Equity Research AI

    Peter Enderlin's questions to LISATA THERAPEUTICS (LSTA) leadership • Q1 2025

    Question

    Peter Enderlin of MAZ Partners asked about several strategic topics, including the feasibility of big pharma manufacturing certepetide for trials, progress on endometriosis partnerships, and the status of developing 'tethered' versions of certepetide.

    Answer

    President and CEO Dr. David Mazzo addressed the questions by stating that big pharma manufacturing is impractical before a deal is signed. He noted that endometriosis partnership discussions are very early-stage, as partners prefer clinical assets. For tethered administration, he highlighted the new research collaboration with Catalent to bind certepetide to their SMARTag ADC platform as a major step forward.

    Ask Fintool Equity Research AI

    Peter Enderlin's questions to LISATA THERAPEUTICS (LSTA) leadership • Q3 2024

    Question

    Asked about the company's strategy for prioritizing its numerous collaboration opportunities, the number of active prospects, whether immunotherapy combinations are viewed as more promising, and the rationale for the structure of the ValoTx partnership.

    Answer

    Opportunities are prioritized via a matrix focusing on data timelines within the funding window, unmet need, and partner funding. Capital is the main constraint on pursuing many live prospects. Early data suggests immunotherapy combinations may be more promising. The ValoTx collaboration structure was chosen for its efficiency, leveraging Valo's in-house expertise and resources, making it simpler and less expensive.

    Ask Fintool Equity Research AI

    Peter Enderlin's questions to LISATA THERAPEUTICS (LSTA) leadership • Q2 2024

    Question

    Inquired about the size of the pediatric pancreatic cancer population and about potential or ongoing collaborations with other companies to combine Certepetide with their investigational drugs.

    Answer

    The executive stated the pediatric pancreatic cancer population is virtually non-existent. Regarding collaborations, they confirmed that Certepetide's mechanism is agnostic to companion drugs and could help both approved and investigational products. They have ongoing dialogues with other companies, which are initiated by both Lisata and potential partners, to find affordable ways to collaborate.

    Ask Fintool Equity Research AI

    Peter Enderlin's questions to GENWORTH FINANCIAL (GNW) leadership

    Peter Enderlin's questions to GENWORTH FINANCIAL (GNW) leadership • Q2 2025

    Question

    Peter Enderlin of MAZ Partners asked about the possibility of Genworth initiating a common stock dividend, particularly in light of the potential proceeds from the successful AXA litigation.

    Answer

    President, CEO & Director Thomas McInerney responded that while the board regularly considers a dividend, the vast majority of shareholders currently prefer that excess cash be used for share repurchases. Therefore, instituting a regular dividend is not part of the company's current plan, though it remains a future possibility.

    Ask Fintool Equity Research AI